Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SNY with free AI briefings, catalyst countdowns, and dilution alerts.

SNY · Sanofi

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$6B Cash on Hand
CF+ Cash Runway
0.6% Short Interest
$54.92 Analyst Target (9)
Follow SNY by email Get an email when SNY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SNY, unsubscribe in one click. Privacy

📣 What SNY Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Imiglucerase
FDA approved May 1994 · Cerezyme
Gaucher's Disease Type III Phase 3 · NCT07927140 Not yet recruiting
Rilzabrutinib
FDA approved Aug 2025 · Wayrilz
Immune Thrombocytopenia Phase 3 · NCT07216079 Active not recruiting
Teriflunomide
FDA approved Sep 2012 · Aubagio
Multiple Sclerosis Phase 3 · NCT07930624 Not yet recruiting
Plerixafor
FDA approved Dec 2008 · Mozobil
Diffuse Large B-cell Lymphoma (DLBCL) Phase 2 · NCT02570542 Active not recruiting
Isatuximab
FDA approved Mar 2020 · Sarclisa
Plasma Cell Myeloma Refractory Phase 1/2 · NCT04643002 Recruiting
Insulin
FDA approved Apr 2000 · Lantus Solostar
Type 1 Diabetes Mellitus Phase 2 · NCT06111586 Active not recruiting
Alglucosidase Alfa
FDA approved Apr 2006 · Myozyme
Glycogen Storage Disease Type II N/A · NCT04848779 Completed
Efanesoctocog Alfa Factor VIII Deficiency Phase 4 · NCT06941870 Recruiting
NVXC19 (EU licensed, standalone) Immunization Phase 3 · NCT07890454 Recruiting
Frexalimab Multiple Sclerosis Phase 3 · NCT06141486 Active not recruiting
IIV-HD + NVXC19 combination Immunization Phase 3 · NCT07890454 Recruiting
IVIg Chronic Inflammatory Demyelinating Polyneuropathy Phase 3 · NCT06290141 Recruiting
Lunsekimig Chronic Obstructive Pulmonary Disease Phase 3 · NCT07190209 Recruiting
Measles, combinations with mumps and rubella… Yellow Fever Immunization Phase 3 · NCT07103148 Active not recruiting
monovalent Hep B vaccine Haemophilus Influenzae Type b Immunisation Phase 3 · NCT07941622 Not yet recruiting
MRI contrast-enhancing agents Multiple Sclerosis Phase 3 · NCT06141486 Active not recruiting

Also used in these trials (approved or third-party drugs, not SNY's own candidates): Belumosudil, Saponin-based Adjuvant, Gemcitabine Hydrochloride, Paclitaxel, Pemetrexed Disodium, Teplizumab, Cemiplimab, Cisplatin, Cholestyramine, Carboplatin, Belantamab Mafodotin, Pomalidomide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SNY holds $6B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SNY files for a raise →

👥 Who Owns SNY

Insiders 0.1% Institutions 12.6% Public and other holders 87.3%
HolderTypeShares% of sharesAs of
AMUNDI Institution (13G, 5%+) 68,832,052 5.64% 2026-09-30
Dodge & Cox Inc. Institution (13F) 15,668,529 1.28% 2026-09-30
Morgan Stanley Institution (13F) 14,900,060 1.22% 2026-09-30
Fisher Asset Management, LLC Institution (13F) 9,597,228 0.79% 2026-09-30
Bank of America Corporation Institution (13F) 7,840,212 0.64% 2026-09-30
JPMORGAN CHASE & CO Institution (13F) 7,330,737 0.60% 2026-09-30
Invesco Ltd. Institution (13F) 6,271,955 0.51% 2026-09-30
Mondrian Investment Partners Ltd Institution (13F) 5,652,139 0.46% 2026-09-30
Federated Hermes, Inc. Institution (13F) 5,455,928 0.45% 2026-09-30
Brandes Investment Partners L.P. Institution (13F) 4,306,275 0.35% 2026-09-30
Boston Partners Institution (13F) 3,999,818 0.33% 2026-09-30
FMR, LLC Institution (13F) 3,967,153 0.33% 2026-09-30

Share count 1,219,427,096 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SNY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.